Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

News

Scrip World Pharmaceutical News was established in 1972 and - since that time - has continued to serve as the leading news and information source for the world's pharmaceutical and biotech industries. Scrip's team of more than 20 writers, analysts and editors provide the latest news, features and commentary from around the globe.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:
    ThromboGenics
    Dr. Patrik De Haes, CEO
    Tel: +32-16-75-13-10
    patrik.dehaes@thrombogenics.com

    Chris Buyse, CFO
    Tel: +32-16-75-13-10
    chris.buyse@thrombogenics.com

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren
    Tel: +44-207-638-95-71
    amber.bielecka@citigatedr.co.uk



'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 A study presented at the ... efficacy of CSL Behring,s C1 Inhibitor (C1-INH) concentrate ... highly sensitized patients. C1-INH is a human protein ... The study shows that post-transplant treatment ... levels of complement components 3 and 4, suggesting ...
(Date:7/30/2014)... Toronto, Canada (PRWEB) July 30, 2014 ... been available in health services research for a ... an upswing in interest regarding the use of ... actual practice conditions. , By combining today’s powerful ... in the digital era, ‘big data’ holds significant ...
(Date:7/30/2014)... 30, 2014   Wyle has been ... Lifecycle Mission Support Services (FILMSS) contract awarded by ... the terms of the contract, Wyle will provide ... Field, Calif. In particular, Wyle will provide program ... projects on the International Space Station and collaborative ...
(Date:7/30/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... in Industrial Applications , the global market for industrial ... by 2018, registering a five-year compound annual growth rate ... recorded in the detergent enzyme segment with a CAGR ... has influenced almost every sector of industrial activity, ranging ...
Breaking Biology Technology:Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Leveraging ‘Big Data’ - Methodological Considerations in Health Services Research, New Webinar Hosted by Xtalks 2Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3
... , , , , , , , Multiporator , , ... , Transfection Protocol , Protocol No. 4308 915.030 ... , , , , , , ... , , Transfection with , ...
... , Multiporator , , , , , , , ... Protocol No. 4308 915.028 11/1999 , , ... , , Cell line , ... , Transfection with , Plasmid pEGFP-N1 ...
... , , Multiporator , , , , , , ... Transfection Protocol , Protocol No. 4308 915.039 12/1999 , , ... , , , Cell ... 15, , , ...
Cached Biology Technology:HeLa 2HL-60 2Embryonic stem cells, mouse 2Embryonic stem cells, mouse 3
(Date:7/30/2014)... of researchers from the University of Helsinki and the ... reproduce in mice morphological changes which have taken millions ... in the embryonic development of mice teeth, induced in ... very similar to those observed in the fossil registry ... years ago. , To modify the development of ...
(Date:7/30/2014)... Sciences Institute (SALSI), a joint venture between The University ... of Texas Health Science Center at San Antonio, has ... The winners, Emily Boice from UTSA and Lei Huang ... their project titled, "Novel engineered ferritins for tracking and ... and Huang,s research is focused on finding a treatment ...
(Date:7/30/2014)... announce its new relationship with the International College of ... partner to publish International Journal of Neuropsychopharmacology ... Alan Frazer, Editor-in-Chief of IJNP said, "Our ... will further facilitate the goal for the IJNP ... within neuropsychopharmacology. The conversion of the IJNP ...
Breaking Biology News(10 mins):Scientists reproduce evolutionary changes by manipulating embryonic development of mice 2OUP to partner with the International College of Neuropsychopharmacology 2
... N.J. -- On Thursday May 22, 2008, Dr. Jon ... Process Specialist for the NJMSC/NJ Sea Grant Program will ... on the condition state of NJ beaches, as we ... will include NJDEP Commissioner Lisa Jackson, Secretary of Agriculture ...
... -- The pipes that rise from oil fields, topped ... and dump carbon dioxide into the air. In new ... material that can turn methane into a safe and ... excess methane into a variety of useful fuels and ...
... in German . Bonn/Berlin. What will the loss of ... economies need to invest now in order to stop the trend" ... not act" These are the questions the TEEB -- The Economics ... pilot study led by Pavan Sukhdev, who is head of Deutsche ...
Cached Biology News:Halting methane squanderlust 2Halting methane squanderlust 3Biodiversity as a natural resource 2
... at the 3, 3', 4, and 4' ... an internal standard for the quantification of ... is the theoretical cyclooxygenase metabolite of dihomo-γ-linolenic ... in the plasma of normal humans or ...
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Direct ELISA Assay Diluent, 10 L...
Direct ELISA Assay Diluent - EDTA, 10 L...
Biology Products: